Phase I
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
Several biotech companies have announced closings of million-dollar financing rounds Monday, with Cambridge, Mass.-based cell and gene therapy company ElevateBio leading the pack. ElevateBio announced it raised $525 million in a Series C financing round, which the company says should help expand its drug programs as well as manufacturing capacity and current and future partnerships.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
The European Medicines Agency has launched a safety review of bluebird bio’s thalassaemia drug Zynteglo, a conditionally licensed gene therapy in Europe.
While existing vaccines are being rolled out worldwide, Novavax’s is demonstrating effectiveness in late-stage trials and the partnership of Sanofi and Translate Bio is beginning early-stage trials for their mRNA vaccine.
Preliminary findings of LentiGlobin suggested that the BB305 LVV vector was present in the AML blast cells, but there was not sufficient information to determine causality.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
PRESS RELEASES